Hypoxia-induced angiogenesis regulator (HIAR)

NCBP2AS2, also known as the **hypoxia-induced angiogenesis regulator (HIAR)**, is a gene located on chromosome 3 (chr3:196942674-196943543, GRCh38) and described as a *protein-coding* or *putative noncoding* gene in different databases[5][8]. It has been referred to as encoding a "KRAS-interacting microprotein," but its protein product and functional roles remain largely uncharacterized. Functional annotation indicates possible roles in **protein binding** and **regulation of angiogenesis under hypoxic conditions**[2][8]. No clear evidence supports its use as a therapeutic target, nor are there documented interacting drugs, mechanisms of action relevant for therapy, or established biomarker or safety concern data. **Summary of context:** - There is significant ambiguity in the molecular classification (long noncoding RNA vs. microprotein); there is no evidence this is a typical receptor, enzyme, transporter, or transcription factor. - Unlike its neighboring sense gene NCBP2 (nuclear cap-binding protein 2), which is a well-defined RNA-binding protein and noted cancer-associated oncogene[1], NCBP2AS2 is not a well-validated, classical therapeutic target, nor is there clear experimental proof for direct disease or drug involvement. - Most references classify this gene in the “other” or “uncharacterized” molecular class, possibly with regulatory or microprotein-coding capacity[5][8].

Other names

NCBP2 antisense 2NCBP2AS2HIARKRASIMNCBP2-AS2KRAS-interacting microproteinNCBP2 antisense gene protein 2NCBP2 antisense RNA 2 (head to head)